Patents by Inventor F. Charles Brunicardi

F. Charles Brunicardi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High definition, color images, animations, and videos for diagnostic and personal imaging applications
    Patent number: 11051769
    Abstract: High definition, color images, animations, and videos for diagnostic and personal imaging applications are described along with methods, devices and systems for creating the images, as well as applications for using the images, animations and videos.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: July 6, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: F. Charles Brunicardi
  • MICROPATTERNED SILICONE OXYGENATING DRESSING FOR CHRONIC WOUNDS
    Publication number: 20210001001
    Abstract: A wound dressing system having an oxygen-permeable membrane having a first surface and a second surface with oxygen-permeable pillars extending from the second surface is described.
    Type: Application
    Filed: March 21, 2019
    Publication date: January 7, 2021
    Applicant: The University of Toledo
    Inventors: Chandan Das, Munier Nazzal, F. Charles Brunicardi
  • HIGH DEFINITION, COLOR IMAGES, ANIMATIONS, AND VIDEOS FOR DIAGNOSTIC AND PERSONAL IMAGING APPLICATIONS
    Publication number: 20190090824
    Abstract: High definition, color images, animations, and videos for diagnostic and personal imaging applications are described along with methods, devices and systems for creating the images, as well as applications for using the images, animations and videos.
    Type: Application
    Filed: September 24, 2018
    Publication date: March 28, 2019
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: F. Charles Brunicardi
  • Therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors
    Patent number: 9133459
    Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: September 15, 2015
    Assignees: Strike Bio, Inc., Baylor College of Medicine
    Inventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi
  • BI-FUNCTIONAL shRNA TARGETING MESOTHELIN AND USES THEREOF
    Publication number: 20130259926
    Abstract: The present invention includes bifunctional shRNAs capable of reducing an expression of a Mesothelin gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Mesothelin, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Mesothelin.
    Type: Application
    Filed: March 28, 2013
    Publication date: October 3, 2013
    Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neil Senzer, Qizhi Yao, Changyi (Johnny) Chen, F. Charles Brunicardi
  • Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors
    Publication number: 20130084331
    Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.
    Type: Application
    Filed: December 4, 2012
    Publication date: April 4, 2013
    Applicants: BAYLOR COLLEGE OF MEDICINE, GRADALIS, INC.
    Inventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi
  • Therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors
    Patent number: 8361983
    Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: January 29, 2013
    Assignees: Gradalis, Inc., Baylor College of Medicine
    Inventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi
  • Treating Insulin Secreting Cells
    Publication number: 20110257250
    Abstract: This invention relates to a recombinant nucleic acid for an RIP-tk (rat insulin promoter-thymidine kinase) construct that selectively targets insulin secreting cells, such as ?-cells, PDX-1 positive human pancreatic ductal carcinomas, and other cells containing certain transcription factors. The present invention is useful in the treatment of pancreatic cancers, such as ?-cell insulinomas and can also be used to target pancreatic tumors that do not express insulin, such as pancreatic adenocarcinoma.
    Type: Application
    Filed: August 26, 2008
    Publication date: October 20, 2011
    Inventor: F. Charles Brunicardi
  • Novel Therapeutic RNA Interference Technology Targeted to the PDX-1 Oncogene in PDX-1 Expressing Neuroendocrine Tumors
    Publication number: 20110117183
    Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.
    Type: Application
    Filed: October 27, 2010
    Publication date: May 19, 2011
    Applicant: GRADALIS, INC.
    Inventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi
  • Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
    Patent number: 6716824
    Abstract: This invention relates to a recombinant nucleic acid for an RIP-tk (rat insulin promoter-thymidine kinase) construct that selectively targets insulin secreting cells, such as &bgr;-cells, PDX-1 positive human pancreatic ductal carcinomas, and other cells containing certain transcription factors. The present invention is useful in the treatment of pancreatic cancers, such as &bgr;-cell insulinomas.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: April 6, 2004
    Inventor: F. Charles Brunicardi